BellaSeno, an ISO 13485-certified medical technology company that develops resorbable scaffolds with additive manufacturing technologies, was awarded the German Innovation Prize by the German Design Council for its Senella technology in the category # W2 Excellence in Business to Business – Medical Technology. BellaSeno was selected from around 700 applicants from 30 countries covering bluechip and innovative start-up companies.
Senella is designed to alleviate the complications and risks associated with current approaches to breast reconstruction and augmentation. Based on a patented, porous scaffold made of an absorbable, biocompatible polymer, which is FDA approved and CE-marked and has been used routinely in clinics for over 30 years, Senella is absorbed over a period of 2 years. The final clinical result is natural soft tissue with no foreign matter residue.
Senella is currently being developed for breast reconstruction and the rare breast defect pectus excavatum. The first tests on humans are in progress.
Mohit Chhaya, Co-Founder and CEO of BellaSeno, said, “The award is an important recognition of our work in the field of natural tissue reconstruction. Our goal is to provide patients and surgeons with safer, more natural alternatives to standard approaches to breast reconstruction. Ultimately, this leads to restore the natural breast. “
